Literature DB >> 29738131

Screening and Treatment Rates for Latent Tuberculosis Among Newly-Arrived Refugees in an Urban Facility in Connecticut.

Dylan Duchen, Andrew T Boyd, Aniyizhai Annamalai.   

Abstract

There is a high prevalence of latent tuberculosis infection (LTBI) and risk of reactivation among refugees. This study describes LTBI prevalence, treatment initiation, and completion rates in refugee patients seen at one urban Connecticut hospital. This retrospective chart review includes 248 adult refugee patients screened between January 2009 and April 2012. Demographics, tuberculin skin test (TST) results, treatment initiation and completion rates, and treatment-related variables were collected. Ninety-eight percent of adult refugees received TST screening and 44.0% were diagnosed with LTBI. Of these, 95.5% initiated treatment, and of those, 48.2% completed treatment. Early treatment discontinuation was high, with 29.5% of patients diagnosed with LTBI defaulting after the first clinic visit. Despite near-universal screening within this refugee population, LTBI treatment initiation and completion rates remain low. Greater efforts should be made to ensure LTBI treatment initiation and completion among refugees through early case management and shorter treatment duration.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29738131

Source DB:  PubMed          Journal:  Conn Med        ISSN: 0010-6178


  2 in total

1.  Minnesota refugees diagnosed with tuberculosis disease, January 1993-August 2019.

Authors:  Kailey Urban; Blain Mamo; Dzung Thai; Alicia Earnest; Emily Jentes
Journal:  BMC Infect Dis       Date:  2022-04-09       Impact factor: 3.090

2.  Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis.

Authors:  Kieran Rustage; Jessica Lobe; Sally E Hayward; Kristina L Kristensen; Ioana Margineanu; Ymkje Stienstra; Delia Goletti; Dominik Zenner; Teymur Noori; Manish Pareek; Christina Greenaway; Jon S Friedland; Laura B Nellums; Sally Hargreaves
Journal:  Lancet Infect Dis       Date:  2021-08-04       Impact factor: 25.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.